Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SHELTON, Conn., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
-
SHELTON, Conn., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
-
First Pivotal Trial Will Evaluate I.V. CR845, Dosed Pre- and Postoperatively, in Patients Undergoing Abdominal Surgery Top-line data expected in 1H'2016 SHELTON, Conn., Sept. 9, 2015 (GLOBE...
-
SHELTON, Conn., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
-
Pain Experts to Discuss Developments in Kappa Opioid Receptor Agonists and the Future of Pain Management Company to Present Positive Data From Phase 2 Acute Pain and Human Abuse Liability...
-
SHELTON, Conn., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
-
Reported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus Completed successful public offering of common stock, raising net proceeds of...
-
SHELTON, Conn., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
-
SHELTON, Conn., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively...
-
SHELTON, Conn., July 29, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...